Peptides as Drugs: Discovery and Development

By covering the full spectrum of topics relevant to peptidic drugs, this timely handbook serves as an introductory reference for both drug developers and biomedical researchers interested in pharmaceutically active peptides, presenting both the advantages and challenges associated with this molecular class.
The first part discusses current approaches to developing pharmaceutically active peptides, including case studies of the use of peptidic drugs in cancer and AIDS therapy. The second part surveys strategies for the development and targeting of peptidic drugs.
With its integration of biochemical, pharmaceutical and clinical research, this work reveals the full picture of modern peptide drug research in a single volume, making it an invaluable reference for medicinal chemists, biochemists, biotechnologists, and those in the pharmaceutical and biotechnological industries.

By covering the full spectrum of topics relevant to peptide drugs, this timely handbook serves as an introductory reference for both drug developers and biomedical researchers interested in pharmaceutically active peptides, presenting both the advantages and challenges associated with this molecular class.

The first part discusses current approaches to developing pharmaceutically active peptides, including case studies of the use of peptidic drugs in cancer and AIDS therapy. The second part surveys strategies for the development and targeting of peptidic drugs.

With its integration of biochemical, pharmaceutical and clinical research, this work reveals the full picture of modern peptide drug research in a single volume, making it an invaluable reference for medicinal chemists, biochemists, biotechnologists, and those in the pharmaceutical and biotechnological industries.

Bernd Groner is the head of the Georg Speyer Haus, an independent biomedical research institute in Frankfurt am Main (Germany). He studied biochemistry at the University of Pittsburgh (USA) and did postdoctoral work at Columbia University in New York, the Max-Planck-Institute for Molecular Genetics in Berlin, and the Swiss Institute for Experimental Cancer Research in Lausanne. From 1993 to 1998, he served as Director of the Institute for Experimental Cancer Research in Freiburg (Germany), before taking up his current post at the Georg Speyer Haus. He is a widely recognized authority on peptide hormones and has pioneered the design of peptides as pharmacological modulators of cell signaling.